Nature Medicine, Published online: 16 June 2026; doi:10.1038/d41591-026-00031-5 Engineered heart muscle allografts derived from induced pluripotent stem cells show promising early outcomes in patients with treatment-refractory advanced heart failure with reduced left ventricular ejection fraction, in support of further clinical investigation.